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Abstract 
Background: The failure in standard triple therapy has recently increased to high levels in China, primarily because of 
insufficient patient compliance, antimicrobial resistance, and high costs. Effective prevention and eradication of Heli-
cobacter pylori (H. pylori) by artificial passive immunization with orally administered bovine antibodies in the milk has 
been demonstrated in many animal studies, but the clinical studies that are available have shown no H. pylori eradica-
tion. This study was to evaluate the efficacy and safety of orally administered bovine anti-H. pylori antibodies for the 
clearance of H. pylori infecting O blood group subpopulations.
Methods: Two local epidemic H. pylori strains that were prevalent locally were screened and then used to immunize 
dairy cows. After confirmation of the presence of anti-H. pylori polyclonal antibodies in the milk by enzyme-linked 
immunosorbent assay, the milk was subsequently defatted and processed into sterile milk by pasteurization. This study 
was designed as a double-blind placebo-controlled randomized clinical trial. Our 61 H. pylori-infected O blood group 
subjects were assigned to two groups; 31 subjects were treated with bovine milk containing antibodies and 30 subjects 
with the placebo. The medication-based study was continued for 28 days. Subjects were followed up for 56 days. The 
effect was assessed by the C-14 urea breath test (UBT). SPSS 17.0 software for Windows was used to analyze the data.
Results: Of the 61 subjects enrolled, 58 completed the protocol. One volunteer in the antibodies group and two vol-
unteers in the control group dropped out. Of the 30 antibody-treated subjects, 13 became UBT negative, whereas none 
of the 30 of the placebo-treated subjects became UBT negative after the medication. Of 13 UBT negative patients, 3 
became positive again at the end of the follow-up. Both intention to treat and per-protocol analysis indicated a signifi-
cant difference in the clearance rate of infected patients between the groups treated with bovine antibody-containing 
milk and the placebo (P = 0.001, P < 0.05) and no significant difference in adverse effects (P > 0.05 all).
Conclusions: Bovine antibody-based oral immunotherapy appears to be safe and has a significant clearance effect 
on intragastric H. pylori that infects O blood group adults.
Trial registration: ChiCTR-TRC-14005212.
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Background
Helicobacter pylori infection is the main cause of gas-
tritis, gastroduodenal ulcer, gastric adenocarcinoma, 
and mucosa-associated tissue lymphoma [1]. Indeed, H. 
pylori was recognized as a category I human carcino-
gen by the WHO/International Agency for Research on 
Cancer (WHO/IARC) in 1994 [2]. The eradication of H. 
pylori is now clearly central to the management of the ill-
nesses described above.
The genotypes of H. pylori are based on two virulent 
genes: cagA and vacA. Different geographic locations 
have different H. pylori genotypes [3]. CagA-positive H. 
pylori is reported to be 60–70% of H. pylori strains iso-
lated from Europe, whereas more than 90% of H. pylori 
strains are cagA positive in eastern Asian countries [4, 
5]. The vacA gene has vacA signal (s) and middle (m) 
regions, which are divided into s1 or s2 and m1 or m2, 
respectively. The vacA s1 region is further divided into 
s1a, s1b, and s1c. The m1 region is further classified into 
m1a, m1b, and m1c, and the m2 region into m2a and 
m2b [6, 7]. Different geographic regions have different 
combination of vacA allele and cagA. These variations in 
the global distribution of the cagA and vacA genotypes 
might account for the diversity of reports associating the 
cagA and vacA genotypes with the clinical outcome from 
these different regions. The serotypes of H. pylori are 
based on the different repeating oligosaccharides units of 
lipopolysacchride (LPS) molecules, whereby six distinct 
H. pylori serotypes (O1–O6) have been defined [8]. Sub-
sequently, detailed structural studies have shown that the 
LPSs of H. pylori are unique in that their O-chain region 
is homologous to mammalian histo-blood group anti-
gens. According to Lewis epitopes present in O-glycans 
and the terminal ABH structures, O-chain components 
of H. pylori are divided into type 1 Lea, Leb, Led, Linear 
B and A determinants; type 2 N-acetyl-lactosamine (Lac-
NAc), Lewisx (Lex), Ley, Sialyl Lex, in monomeric and pol-
ymeric forms [9]. Like the genotype, the Lewis epitope of 
H. pylori has geographic variations. H. pylori strains from 
Asian population seem to have a higher tendency to pro-
duce the type 1 antigens, Lea and Leb, whereas those iso-
lated from North American and European hosts express 
mainly the type 2 antigens, Lex and Ley. Some of H. pylori 
attach to the epithelium via BabA, SabA, and probably 
other adhesins. Epidemiologically, individuals of the O 
blood group are particularly prone to H. pylori infection 
because their gastric epithelium highly expresses the Leb 
antigen, which is the BabA of H. pylori binding sites [10, 
11].
The eradication rate after standard triple therapy has 
declined below 80% in most areas and has many adverse 
effects [12–14]. With the widespread use of antibiotics, 
the increased resistance to antibiotics and their expensive 
costs make eradication difficult in China [15]. New thera-
peutic strategies are needed to solve the problems men-
tioned above. The approach of passive immunization 
with orally administered antibodies against H. pylori is 
likely to constitute one of the new therapeutic strategies 
[16]. This approach mimics naïve protection in humans 
and has been shown to be effective in the prevention and 
treatment of a variety of pathogens, such as Rotavirus, 
Clostridium difficile, and Campylobacter jejuni [17–21]. 
Many animal studies have shown that bovine antibody-
containing milk against H. pylori reduces bacterial load, 
thus preventing and even eradicating H. pylori infection 
[22–25]. However, the available clinical studies of bovine 
antibodies in milk have not shown H. pylori eradication 
[26–29]. Few clinical studies have been reported based 
on screening the local epidemic H. pylori strains accord-
ing to Lewis blood group structure and the vacA allele to 
immunize diary cows. This clinical study was therefore 
performed to evaluate the efficacy and safety of specific 
anti-H. pylori polyclonal bovine antibodies in milk for 




Two local epidemic strains in Shijiazhuang city were 
screened by sequencing the vacA allele and CagA gene 
(Table 1) of a total of 276 H. pylori strains that were iso-
lated and collected between March 2008 and August 
2011 from the gastric antrum or corpus of patients 
who had undergone endoscopy at the Fourth Hospital 
of Hebei Medical University [30, 31]. The two H. pylori 
strains were named Hp5162 and Hp4236, and the vacA 
genotype was respectively s1a/m2 (127/276) and s1a/m1 
(87/276), both of which were CagA-positive and isolated 
from O blood group patients. The phenotype of the Lewis 
blood-group antigens in the LPS of two H. pylori strains 
was analyzed by serological studies, by using Lewis 
blood-group-specific Lea, Leb, Lex, Ley monoclonal anti-
bodies (Santa Cruz Biotechnology Inc, Dallas, TX, USA) 
on whole cells by enzyme-linked immunosorbent assay 
(ELISA), respectively, with both indicating the presence 
of the type-1 Leb epitope on the cell surface [32, 33]. Two 
H. pylori strains, which were preserved as frozen stocks 
at −80°C in brain heart infusion media supplemented 
with 20% glycerol and 10% fetal bovine serum (FBS), were 
revived and cultured on Columbia Agar medium plates 
(Oxoid Ltd., Basingstoke, Hampshire, England) sup-
plemented with 10% defibrinated sheep blood, 5  mg/L 
trimethoprim, 5 mg/L polymixin-B, 5 mg/L amphotera-
cin-B, and 10  mg/L vancomucin (all antibiotics were 
purchased from Solarbio, Beijing, China), under micro-
aerobic conditions (10% CO2, 85% N2, 5% O2) at 37°C for 
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3–10  days with 95% humidity. H. pylori bacterial cells 
were harvested from 9-cm Agar plates with a sterile loop. 
The H. pylori bacterial cells were washed with sterile 0.9% 
normal saline three times, suspended in 0.1 mol/L phos-
phate-buffered saline (PBS) for use as vaccines, and kept 
at −80°C until required.
Immunization of dairy cows
The Animal Care Committee of Hebei Academy of 
Agriculture and Forestry Sciences approved the immu-
nization protocol. Four pregnant dairy bovines were 
vaccinated with the mixture of Hp5162 and Hp4236 H. 
pylori for a total of 8 times, 2 times during the last month 
before parturition, and 6 times after parturition. Vaccina-
tion was performed each time with 6 × 109 cfu H. pylori, 
by means of intranasal mucosal drip, supramammary 
lymph node (subcutaneous), and hip muscle administra-
tion at four sites (once every 2 weeks). Dairy cows were 
boosted at about 2-week intervals. The H. pylori suspen-
sion was emulsified with an equal volume of Freund’s 
complete adjuvant for the initial immunization and Fre-
und’s incomplete adjuvant for each of the boosts. Milk 
and serum samples were collected from each cow before 
immunization and 50  days after immunization for the 
detection of antibodies by ELISA.
Detection of antibody by ELISA
Overnight cultures of bacteria were collected by cen-
trifugation (5,000×g, 10  min, 4°C), washed three times 
with PBS, and repelleted at 10,000×g for 2  min. Total 
proteins were extracted by using the ProteoPrep® Sam-
ple Extraction kit (Sigma-Aldrich Corporation, St. Louis, 
MO, USA) according to the manufacturer’s instructions. 
The protein concentration was measured by the Pierce™ 
BCA Protein Assay kit (Thermo Fisher Scientific Inc, 
Waltham, MA, USA). Microplates were pretreated with 
2.5% glutaraldehyde, and each ELISA plate was coated 
with 100  µl H. pylori at a concentration of 1  mg/mL in 
PBS and incubated overnight at 4°C. The coated wells 
were blocked with PBS containing 2.5% bovine serum 
albumin (Sigma-Aldrich Corporation, St. Louis, MO, 
USA) for 2 h at 37°C. A 100 µL milk sample, which was 
diluted 1:200, 1:400, 1:800, and 1:1,200 with PBS contain-
ing 0.05% Tween 20 was dispensed to the microplate. 
Horseradish-peroxidase-conjugated goat anti-bovine IgG 
antibody (Southern Biotechnology Associates Inc, Bir-
mingham, AL, USA) which was diluted 1:8,000 and tetra-
methylbenzidine peroxide substrate systems were used as 
the secondary antibody and the substrate, respectively. 
Absorbance at 450  nm (A450) was measured after the 
reaction was terminated with 1 M H2SO4. The maximal 
milk dilution giving an A450 of 0.5 was expressed as the 
antibody titer.
Disinfection of milk
The presences of antibodies were confirmed by ELISA, 
and the antibody titer attained a peak (1:800) by serial 
detection. The cow antibody-containing milk was then 
collected, defatted, processed into sterile milk by pas-
teurization, and stored at −20°C until required. Similarly, 
milk prepared from non-immunized cows was used as 
the placebo.
Clinical trial
The study protocols were approved by the Ethics Com-
mittee of Hebei Medical University Fourth Hospital 
according to Declaration of Helsinki criteria. All subjects 
were provided with a notice of written consent before 
enrollment. Because of the exploratory nature of this 
study, the sample calculation was based on previous lit-
erature of about 1–5%/year spontaneous clearance rate 
of H. pylori infection [34]. Based on Fisher’s exact test 
with a unilateral hypothesis and an expectation of an 
increase in the eradication rate of 30% with bovine anti-
H. pylori antibodies compared with the 5%/year spon-
taneous clearance rate of the infection, the sample size 
was calculated to be 28 patients for each group of either 
the antibody milk or placebo group for a power of 0.80 
and a significance level of 0.05. The clinical study was 
designed to be a randomized double-blind placebo-con-
trolled trial. The randomization was carried out by using 
a list obtained by computerization. Patients received 
their numbers in an ascending order for enrollment. This 
number corresponded to the randomized regimen for the 
use of medication with antibody milk or placebo. None 
of the patients were aware of the randomization, and the 
investigators, who were also blinded to the randomiza-
tion, followed the treatment and performed all examina-
tions independently.
416 volunteers from Shijiazhuang city were enrolled 
for the trial, the volunteers population consisting of 233 
men and 183 women with a mean age of 39 (age range 
20–67). First, the patients infected with H. pylori were 
screened by detecting anti-H. pylori IgG antibody in the 
volunteer’s serum by using the ASSURE H. pylori Rapid 
Test kit (MP Biomedicals LLC, Santa Ana, CA, USA). 
Second, volunteers with positive serum antibodies were 
confirmed as being infected with H. pylori by the carbon-
14-labeled urea breath test. According to the inclusion 
and exclusion criteria, 61 volunteers (34 males and 27 
females) were enrolled in the clinical trial and randomly 
assigned to either the antibody milk (in total 31 subjects, 
15 males and 16 females, age range 21–57, mean 36) or 
placebo (in total 30 subjects, 19 males and 11 females, age 
range 26–63, mean 42) group. Inclusion criteria were sub-
jects who were enrolled were over 18  years old with H. 
pylori infection and the O blood group, with no previous 
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treatment for the infection and no use of anti-inflamma-
tory or antibiotic drugs within 4  weeks prior to enroll-
ment. Exclusion criteria were subjects were excluded 
with lactose intolerance, pregnancy or lactation, malig-
nancy, significant systemic comorbidity, over 80  years, 
a history of gastrointestinal surgery, erosive esophagitis, 
or use of low-dose aspirin. Patients who had undergone 
previous treatment for H. pylori infection with standard 
therapy were also excluded.
The stored cow milk was thawed and warmed at 37°C 
prior to use. Based on the recommended daily amount 
of the consumption of milk, all subjects received either 
200 mL immune-milk + 1 mL NaHCO3 (1 mol/L) or pla-
cebo + 1 mL NaHCO3 (1 mol/L) once a day, 1–1.5 h after 
dinner for 28  days. The follow-up period was 56  days. 
14C-urea breath tests were performed three times, namely 
at the start of the study, after completion of the study med-
ication, and at the end of the follow-up. The questionnaires 
for adverse events were completed at the 7, 14, 28, and 
56 days; all patients answered a questionnaire on dyspep-
tic symptoms and the most common symptoms related to 
possible adverse effects attributable to treatment (Table 2). 
Each symptom was quantified as –(0), +(1), ++(2), and 
+++(3). The questionnaire allowed the inclusion of new 
symptoms that were considered as adverse effects in the 
assessments after antibody milk administration. The num-
ber and grade of symptoms in all patients were evaluated. 
Previous symptoms that increased in grade during and 
after treatment were also considered as adverse effects.
Data analysis
A statistical analysis was performed by using SPSS 17.0 
software for Windows. The Pearson Chi Square test was 
used to compare variables for clearance and adverse effect 
incidence, and a two-sided P < 0.05 was considered statis-
tically significant. The grades of adverse events at 7, 14, 28, 
and 56 days were evaluated by the Mann–Whitney test by 
using the value obtained from the symptom questionnaire.
Results
One volunteer in the antibody group and 2 volunteers in 
the control group dropped out of the trial because they 
had moved out of the region; 58 subjects completed the 
study with 30 in the antibody group and 28 in the placebo 
group (Figures  1, 2). The clearance efficacy of the anti-
body milk was evaluated according to the results of the 
14C-urea breath tests; 13 of 30 antibody-treated subjects 
became UBT negative, whereas none of the 30 placebo-
treated subjects became UBT negative after comple-
tion of the study medication; 3 of the 13 UBT-negative 
subjects became positive at the end of the follow-up. 
The per-protocol (PP) and intention to treat (ITT) with 
antibody milk and with placebo both indicated a signifi-
cant difference in the clearance rate of infected patients 
between the bovine milk containing antibodies and the 
placebo-treated group (P =  0.001, P < 0.05). No signifi-
cant differences were seen in the score of adverse effect in 
the antibody group compared with the placebo group on 
7, 14, 28, and 56 days (P > 0.05 for all).
Safety
None of the patients experienced adverse effects attrib-
utable to the antibody milk treatment, and the antibody 
milk was well tolerated.
Discussion
The previous in vitro studies have demonstrated the good 
effects of treatment with bovine antibody-containing 
milk, but the in vivo clinical studies that are available have 
shown no H. pylori eradication [22–29, 35, 36]. More 
studies on a variety of factors such as the optimal length 
of treatment, the optimal antibody dose, adjunctive acid 
suppression, are needed to solve the discrepancy of out-
come between the in vitro and in vivo investigations.
Helicobacter pylori inhabits the 100  µm-thick mucus 
layer, particularly the 25 µm close to the gastric epithe-
lial cells [37]. Previous literature has shown that pH 
influences the extent of binding of H. pylori-specific anti-
bodies in the milk to H. pylori, with no binding being 
observed under pH 4.0 and maximum binding at pH 7–8 
[38]. Thus, NaHCO3 has to be added to the milk so that 
the elevation in mucus pH can decrease the viscosity of 
the mucus and contribute to the penetration of antibod-
ies into the mucus.
The main problems with the use of antibodies to pre-
vent and control infectious diseases are the variability 
Table 2 Symptom questionnaires
+++ Symptom interferes with normal activity >50% of evaluated time, ++ 
symptom interferes with normal activity <50% of evaluated time, + symptom 
does not interfere with normal activity, – without symptoms.












Values 0 1 2 3
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of the antigen. The genotype and serotype of H. pylori 
of different regions varies significantly from country 
to country, and even between regions within the same 
country [39, 40]. Previous studies have indicated that the 
H. pylori-specific antibodies bind to different clinically 
isolated H. pylori stains with less than a tenfold varia-
tion in titer [38]. Our clinical trial has shown a positive 
effect and safety in O blood group H. pylori-infected 
subpopulations following the oral administration of pol-
yclonal antibodies in defatted milk, in which casein has 
not been discarded considering that casein can elevate 
mucus pH. However, to date, an effective treatment of 
the H. pylori infection has proven difficult, considering 
costs, adverse effects, and the increasing emergence of 
antibiotic-resistant strains [12, 13, 15, 41, 42]. The use of 
anti-H. pylori bovine antibodies in milk to control the H. 
Screened population 
n=416





     (n=31) 
Placebo 
       (n=30) 
UBT (-) 
(n=13) 
carbon-14-labeled urea breath +
Excluded (n=10), 
Did not meet inclusion criteria (n=7) 















Assessed for eligibility (n=71) 
O type blood group  
UBT (-) 
(n=10) 
At end of 28 days 
of treatment period 
Two patients dropped 
out because of leaving 
Shijiazhuang
56 days post  
treatment period 
One patient dropped 
out because of leaving 
Shijiazhuang 
At start of study 
Figure 1 Patient flow in the pilot study with bovine anti-Helicobacter pylori antibodies in milk.
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pylori infection has many advantages such as low costs, 
nutrients, and good compliance, without the develop-
ment of antibiotic resistance in H. pylori or other flora 
and the tolerance of long-term use. Many factors might 
influence the clinical effect, including the different pH 
microenvironments between patients, the antibod-
ies titers in the milk, high gastric acidity, a high bacte-
rial load, persistent infection, bacterial self-protecting 
mechanisms (such as the flagella of H. pylori, which are 
covered by a flagellar sheath and therefore are thought to 
be shielded from antibody selection), the different blood 
types of patients, the genotype deference between immu-
nized and infected bacteria, the optimal length and dose 
of treatment, the oral administration time, and the size 
of the study population. However, the degree of match 
between the immunization and the patient infection 
strains might be the crucial in influencing the effect of 
the clinical trial. Therefore, we have selected the locally 
prevalent H. pylori stains to immunize the dairy cows. 
H. pylori possesses an enormous genomic diversity and 
plasticity that facilitate host adaptation. Simultane-
ously, many studies have suggested that H. pylori has 
Enrollment 









Lost to follow-up n=0
Discontinued intervention (n=1) 
because of leaving Shijiazhuang 
Randomized n=61
Assessed for eligibility n=71
Did not meet inclusion criteria and 
refused to participate n=10
Included in analysis n=31
I.t.t analysis (n=31) 
PP analysis (n=30) 
Included in analysis n=30
I.t.t analysis (n=30) 
PP analysis (n=28) 
Analysis 
Lost to follow-up (n=2)  
because of leaving Shijiazhuang 
Discontinued intervention n=0
Follow-Up 
Figure 2 Consort diagram. ITT intention to treat, PP per protocol.
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a much higher recombination rate and mutation than 
most other microorganisms [43]. Variable expression of 
fucosyltransferases enables H. pylori strains to alter their 
host-recognizable antigens by mimicking human Lewis 
antigens in order to evade their host’s immune response 
[9, 44]. Genetic diversification of the H. pylori adhesin 
genes might allow the adaptation of adherence proper-
ties to better facilitate persistence, despite host defenses. 
The different genotypes of H. pylori have their respec-
tive phenotypes with regard to cell envelope and surface 
structure, especially their adhesins [45]. Different adhes-
ins bind different antigens [46, 47]. For example, adhesins 
SabB and SabA bind sialic acid, and adhesin BabB binds 
Lewis b antigen [47, 48]. Frequent H. pylori infection in 
crowded living conditions and the clustering of the cases 
occurring within family units indicate that different 
regions have different locally prevalent strains. The local 
prevalent H. pylori strains must therefore be selected to 
immunize the dairy cows. However, the overall efficacy of 
the 33.3% (10/30) clearance rate in our study is low and 
is not suitable clinically for the treatment of H. pylori 
infection. This might be because the selected immuniza-
tion strain was not the actual locally prevalent strain in 
our study because we screened a single vacA gene locus. 
More gene loci such as the genes of the flagellum and 
adhesins need to be screened.
Breast-feeding during the first months after birth 
decreases human infant morbidity and mortality from 
diarrheal and systemic infection because the colostrum 
conveys protection to the immunologically naïve infant 
against a variety of microbial pathogens by immuno-
globulins [49]. Whole bovine immune-milk mimics nat-
ural protection in humans and has been used in infants 
for the treatment or prevention of enteric infections 
by bacterial, viral, and protozoal pathogens. H. pylori 
expresses adhesins of BabA/B, SabA, AlpA/B, OipA, and 
HopZ, which confer intimate adherence to the gastric 
epithelium, whereby the bacteria can gain easy access to 
nutrients from host tissues [10, 11, 37, 46, 48]. Antibod-
ies against BabA/B, SabA/B, AlpA/B, OipA, HopZ, and 
urease can disrupt the ability of H. pylori to colonize the 
gastric mucosa and limit its ability to garner essential 
nutrients. Our study might have been limited by the fact 
that we did not ascertain whether milk taken from immu-
nized cows contained the specific antibodies mentioned 
above. Therefore, future research is necessary to ascer-
tain the type of antibodies described above.
At the end of the follow-up, 3 of the 13 UBT-negative 
patients relapsed partly because of the existence of bac-
teria in the intercellular junctions or the intracellular 
submucosa which the bovine antibodies were unable to 
reach in sufficient concentrations to block the bacteria. 
Recent studies have indicated that the oral cavity is not 
only a potential reservoir for H. pylori infection of the 
stomach, but also a potential reservoir for re-infection. 
Previous studies have indicated that patients with oral H. 
pylori are at a significantly greater risk of gastric reinfec-
tion following successful therapy [50, 51]. Another expla-
nation is that mixed infections by two or more strains are 
common in China [52].
Conclusions
Although the bovine antibody-based oral immuno-
therapy demonstrated good effects on controlling the H. 
pylori infection in our study, it cannot fully replace the 
therapeutic strategies with antibiotics, because of the 
small size of the investigated population. Further studies 
on larger populations and the relationships between the 
genetic diversity and pathogenicity of H. pylori strains, an 
analysis of the volunteers’ H. pylori genotype and pheno-
type, and the selection of the actual locally prevalent H. 
pylori stains will be required before this particular novel 
and potentially therapeutic strategy for the eradication of 
this microorganism can be fully developed.
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